Bicyclol - OmicsDI

Show results for

Unknown (15)
Genomics (2)
Metabolomics (1)
Proteomics (1)

Organisms

Enterocloster asparagiformis (1)
Clostridium pacaense (1)
Enterocloster citroniae (1)
Spongospora subterranea (1)
Geobacillus thermodenitrificans NG80-2 (1)
Vibrio cholerae O395 (1)
Synechocystis sp. PCC 6803 substr. GT-T (1)
Arma chinensis (1)
Candida dubliniensis CD36 (1)
Idas modiolaeformis (1)
Limnospira maxima (1)
Rhodotorula toruloides NP11 (1)
Millerozyma acaciae (1)
Aquifex aeolicus (1)
Cryptococcus neoformans (1)
Haemophilus influenzae Rd KW20 (1)
Acidianus brierleyi (1)
Conus caracteristicus (1)
Escherichia coli HT115 (1)
Lathyrus sativus (1)
Conus zonatus (1)
Candidatus Glomeribacter (1)
Linnemannia elongata AG-77 (1)
Campylobacter jejuni subsp. jejuni NCTC 11168 = ATCC 700819 (1)
Anthozoa (1)
Serratia phage JS26 (1)
Acinetobacter baumannii 1656-2 (1)
Serratia ureilytica (1)
Cupriavidus pinatubonensis JMP134 (1)
Soa (1)

Repository

ENA (2)
MetaboLights (1)
pride (1)

Tissue

Liver (1)

Technology Type

Mass spectrometry (1)
Mass Spectrometry (1)
Shotgun proteomics (1)

Instrument Platform

Liquid Chromatography MS - negative - reverse phase (1)
Liquid Chromatography MS - positive - reverse phase (1)

Publication Date

2025 (1)
2023 (1)

Metabolite Name

Nb-Hexacosanoyltryptamine (1)
Pexidartinib (1)
Chloro-{methyl-[1-(2-methyl-5,6-dihydro-[1,4]oxathiin-3-yl)-methanoyl]-amino}-benzoic acid, isopropyl ester (1)
N-Pyridazin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methylidene]piperidine-1-carboxamide (1)
Cer(d18:2(4E,14Z)/18:3(9,11,15)-OH(13)) (1)
Monohydroxytriacetyltaxine (1)
3-[2-[3,4,5-Trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl]-2,3-dihydrofuro[3,2-g]chromen-7-one (1)
Pentacosanoylcarnitine (1)
2-Hexadec-7-enyloctadecanedioic acid (1)
Magnesium octanoate (1)
2-Sulfamoyl-5-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzoic acid (1)
Tesofensine (1)
Psoberan (1)
N-(1,3-Benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide (1)
6,7-Dichloro-5-(N,N-dimethylsulfamoyl)-2,3-dihydrobenzofuran-2-carboxylic acid (1)
(2E,4E,7E)-nona-2,4,7-trienedioyl-CoA (1)
2-[1-(2-Fluorophenyl)ethylamino]-5-methyl-5-(trifluoromethyl)-1,3-thiazol-4-one (1)
1H-Cyclohepta(ghi)perylene-5,12-dione, 3-acetyl-6,11-dihydroxy-4,8,9,13-tetramethoxy-2-methyl- (1)
Dansyl hydrazine (1)
Theasaponin E3 (1)
Fluoresceine isothiocyanate (1)
1,3,7-Trimethyl-8-(1,3,7-trimethyl-2,6-dioxo-8H-purin-9-yl)purine-2,6-dione (1)
Abt-751 (1)
Benzoic acid, 2-[[3-(2-quinolinylmethoxy)phenyl]amino]- (1)
(3S,5R,6S)-6-[2-(3-Benzoylphenyl)propanoyloxy]-3,4,5-trihydroxyoxane-2-carboxylic acid (1)
2-[(Acridin-9-ylamino)methyl]-4-[bis(2-chloroethyl)amino]butanoic acid (1)
7,4'-Dimethoxyflavone (1)
3-Benzo[1,3]dioxol-5-yl-5-hydroxy-5-(4-methoxy-phenyl)-4-(3,4,5-trimethoxy-benzyl)-5H-furan-2-one (1)
5-O-Ethyl 3-O-methyl (4R)-4-(2,3-dichlorophenyl)-2,6-dimethyl-3,4-dihydropyridine-3,5-dicarboxylate (1)
2,8-Dihydroxy-3,4,7-trimethoxy-dibenzofuran (1)

Release Date

2022 (5)
2021 (3)
2023 (2)
2020 (2)
2026 (1)
2025 (1)
2019 (1)

Lab affiliation

Shenzhen Center for Disease Control and Prevention (1)

First Public Date

2024 (2)

Previous page
1 / 2
You're on page 1
page 2
Next page

Sort by:

Relevance

Page size

Bicyclol attenuates high fat diet-induced nonalcoholic fatty liver disease/nonalcoholic steatohepatitis through modulating multiple pathways in mice.

The pathological progression of nonalcoholic fatty liver disease (NAFLD) is driven by multiple factors, and nonalcoholic steatohepatitis (NASH) represents its progressive form. In our previous studies, we found that bicyclol had beneficial effects on NAFLD/NASH. Here we aim to investigate the underl...

ORGANISM(S): Mus musculus (Mouse)

2023-03-23 | PXD040233 | Pride